We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Report Sees Slowing Growth in PET Scans

By MedImaging International staff writers
Posted on 29 Aug 2012
The growth rate of PET (positron emission tomography) and PET/CT (computed tomography) medical imaging scans in the United States began to slow in 2011, with an estimated 1.85 million clinical PET patient exams performed in 2011, down from a double-digit growth rate reported in previous years, according to a new market research report by the IMV Medical Information Division.

“The estimated 1.85 million clinical PET patient studies performed in 2011 represent a 6% increase over IMV’s estimate of 1.74 million patient studies performed in 2010,” observed Lorna Young, senior director, market research at IMV (Des Plaines, IL, USA). “This represents a continued slowing in the annual growth rate for PET patient studies."

The current numbers compare to annual growth from 2008 to 2010 of about 7%, and to annual growth between 2005 and 2008 of 10%. Ms. Young noted that in 2011, most of the growth was from an increase in the number of sites providing PET services; the average procedure increase per site was only 0.6% when compared to 2010. These PET studies were performed in 2,210 hospital and nonhospital sites, using fixed or mobile PET/CT or PET scanners.

Oncology continues to drive the use of PET imaging procedures, as hospitals open cancer treatment centers and install PET/CT scanners to support their oncology services. The study found that about 94% of all PET studies in 2012 were for cancer, distributed between diagnosis (19%), staging (38%), treatment planning (13%), and follow up (30%). Neurology and cardiology applications make up the remaining 6% of procedures, divided evenly between the two.

Used for 96% of all PET procedures in 2011, fluorine-18 fluorodeoxyglucose (FDG) is still the mainstay of PET imaging. Rubidium-82, the next most frequently used radiopharmaceutical, was used for about 2% of all procedures, as problems with the supply of the radiopharmaceutical continued to limit its use for cardiac perfusion studies.

IMV is a leader in market research and online publishing for the medical imaging and clinical diagnostic instruments markets.

Related Links:
IMV



New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
3T MRI Scanner
MAGNETOM Cima.X
New
Ultrasound Imaging System
P12 Elite
New
Doppler String Phantom
CIRS Model 043A

Latest Industry News News

Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy

Mindray Partners with TeleRay to Streamline Ultrasound Delivery

Philips and Medtronic Partner on Stroke Care